Roche Pharmaceutical Development and Sales Overview

Ronapreve Global sales CHFbn CER growth -36% Regional sales 1.2 1.0 0.8 0.6 0.4 0.2 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 631m CER growth International -49% Europe -81% Japan 42% · EU: Limited sales potential left as Ronapreve has low activity against Omicron variants . Japan: Additional sales of CHF 1.1 bn to the government expected in Q4 (overall CHF 1.6 bn for FY 2022) CER-Constant Exchange Rates Roche 165

View entire presentation